HLTH vs. AXDX, TLIS, OMIC, TBIO, PRPO, RPID, BNGO, FLGC, TXMD, and DMTK
Should you be buying Cue Health stock or one of its competitors? The main competitors of Cue Health include Accelerate Diagnostics (AXDX), Talis Biomedical (TLIS), Singular Genomics Systems (OMIC), Telesis Bio (TBIO), Precipio (PRPO), Rapid Micro Biosystems (RPID), Bionano Genomics (BNGO), Flora Growth (FLGC), TherapeuticsMD (TXMD), and DermTech (DMTK). These companies are all part of the "medical" sector.
Accelerate Diagnostics (NASDAQ:AXDX) and Cue Health (NASDAQ:HLTH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.
Accelerate Diagnostics currently has a consensus target price of $1.00, suggesting a potential upside of 8.13%. Cue Health has a consensus target price of $3.00, suggesting a potential upside of 2,042.86%. Given Accelerate Diagnostics' higher probable upside, analysts clearly believe Cue Health is more favorable than Accelerate Diagnostics.
Accelerate Diagnostics has higher earnings, but lower revenue than Cue Health. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Cue Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Accelerate Diagnostics and Accelerate Diagnostics both had 2 articles in the media. Cue Health's average media sentiment score of 0.00 beat Accelerate Diagnostics' score of -0.07 indicating that Accelerate Diagnostics is being referred to more favorably in the media.
17.1% of Accelerate Diagnostics shares are owned by institutional investors. Comparatively, 45.5% of Cue Health shares are owned by institutional investors. 43.6% of Accelerate Diagnostics shares are owned by company insiders. Comparatively, 12.5% of Cue Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Accelerate Diagnostics received 353 more outperform votes than Cue Health when rated by MarketBeat users. Likewise, 63.55% of users gave Accelerate Diagnostics an outperform vote while only 7.14% of users gave Cue Health an outperform vote.
Accelerate Diagnostics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Cue Health has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.
Accelerate Diagnostics has a net margin of -454.95% compared to Accelerate Diagnostics' net margin of -526.48%. Cue Health's return on equity of 0.00% beat Accelerate Diagnostics' return on equity.
Summary
Accelerate Diagnostics beats Cue Health on 10 of the 17 factors compared between the two stocks.
Get Cue Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cue Health Competitors List
Related Companies and Tools
